MC4R Inhibitors
1 drugsAbout MC4R
The melanocortin 4 receptor (MC4R) is a G protein-coupled receptor crucial in regulating energy homeostasis. It plays a key role in energy balance, making it a compelling drug target, especially in the metabolic therapeutic area.
Currently, there is no genetic evidence available linking MC4R to specific diseases. However, its established function in energy balance supports pharmacological intervention for metabolic disorders.
One FDA-approved drug, IMCIVREE, targets MC4R, highlighting the therapeutic potential of this receptor. IMCIVREE, a small molecule, is marketed by RHYTHM for 5 indications in the metabolic therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Multiple Pituitary Hormone Deficiency Genetic Form with only 1 trials.
Top Drugs
RHYTHM is the only company with an approved drug targeting MC4R.
The market is highly concentrated, suggesting high barriers to entry or limited commercial opportunity.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets MC4R, using small molecule modality.
Explore opportunities to develop novel biologics targeting MC4R to diversify the therapeutic landscape.
Clinical Trials 39 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 11 | 0 | 1 | 100% |
| Phase 2 | 11 | 9 | 0 | 2 | 100% |
| Phase 3 | 11 | 7 | 0 | 3 | 100% |
| Phase 4 | 5 | 3 | 1 | 1 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2020 - 2020)
The first and only drug targeting MC4R, IMCIVREE, was approved in 2020.
Recent approval suggests a growing interest in MC4R, but market saturation is low, indicating potential for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (11 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 28 clinical trials targeting MC4R.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities